Moleculin Biotech
MBRX
MBRX
23 hedge funds and large institutions have $4.44M invested in Moleculin Biotech in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.68% more ownership
Funds ownership: 0.48% → 1.16% (+0.68%)
Holders
23
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.75M | |
| 2 | +$55.5K | |
| 3 | +$42.9K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$16.7K |
| 5 |
Renaissance Technologies
New York
|
+$8.05K |
Top Sellers
| 1 | -$116K | |
| 2 | -$13K | |
| 3 | -$6.33K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.1K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$4.29K |